NCT04551053 2025-10-02To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte CorporationPhase 3 Terminated177 enrolled 15 charts
NCT02998476 2025-08-22A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)Incyte CorporationPhase 2 Completed60 enrolled 15 charts
NCT03144674 2025-07-11A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)Incyte CorporationPhase 2 Completed110 enrolled 18 charts